Walking improves the cognitive function of schizophrenic subjects
Not Applicable
Completed
- Conditions
- SchizophreniaMental and Behavioural Disorders
- Registration Number
- ISRCTN14763786
- Lead Sponsor
- niversity of Ferrara
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35337370/ (added 28/03/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. Patients diagnosed with schizophrenia since at least 1 year
2. On antipsychotic medications with the same therapeutic regimen for at least 3 months before enrolment
3. Free of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with the walking activity
Exclusion Criteria
1. Recent modification of therapeutic regimen
2. Presence of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with the walking activity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Feasibility was evaluated through the number of dropouts between baseline the end of the study<br> 2. Adherence was measured by the number of walking sessions attended by the participants during the one year program (using patient records)<br> 2. Cognitive function assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP) and the Frontal Assessment Battery (FAB) at baseline and after one year.<br>
- Secondary Outcome Measures
Name Time Method <br> Cardiovascular risk factors were evaluated only in the subjects that followed the walking program (at baseline and after 1-year, at the end of the walking program):<br> 1. Blood pressure (mmHg, sphygmomanometer)<br> 2. Anthropometric variables - height (m), weight (kg), BMI (kg/m² and waist circumference (cm)<br> 3. VO2peak was indirectly determined using the 1-kilometer walking test (1k-WT). Five minutes of slow walking preceded the test. Subjects were instructed to select a pace that they could maintain for 10 to 20 min at a moderate perceived exercise intensity, (11–13 on the 6–20 Borg scale). Heart rate was monitored continuously using a Polar Accurex Plus heart rate monitor (Polar Electro, Kempele, Finland). The equation for VO2 peak determination considering age, BMI, HR and time to complete the 1 k-TWT was then applied<br>